VAX-24
Invasive Pneumococcal Disease (IPD) in Infants
Phase 2Active
Key Facts
About VaxCyte
VaxCyte is a clinical-stage biotech company on a mission to eliminate invasive bacterial infections through superior vaccine engineering. Its core competitive advantage is the XpressCF® cell-free protein synthesis platform, which enables the precise, carrier-sparing design of broad-spectrum conjugate vaccines. With its lead candidate, VAX-31, in a comprehensive Phase 3 program and a robust pipeline targeting major bacterial pathogens, VaxCyte is positioned to potentially set new standards of care in the multi-billion-dollar pneumococcal vaccine market and beyond.
View full company profile